Ifeyinwa Chioma Ezeala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ifeyinwa Chioma Ezeala has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Tsang-Hsien Wu
The Ph.D. Program of Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan
1 shared publication Charity Ukamaka Obiora
1 shared publication- Cheng-Ta Lai
Division of Colon and Rectal Surgery, Department of Surgery, MacKay Memorial Hospital, Taipei 104217, Taiwan
1 shared publication Chidimma Maryann Enendu
1 shared publicationChidozie Innocent Anyadiegwu
1 shared publication- Chioma Grace Enwolo-Chibueze
Ph.D. Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan
1 shared publication
Latest Publications
- Open Access
- 9 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 8780
Integrated In Silico and Experimental Validation of Antrocin as a Plant-Derived Multi-Target Therapeutic for BRAF/MEK/PI3K-Driven Colorectal Cancer
Colorectal cancer (CRC) remains a leading cause of cancer-related death worldwide, with resistance to targeted therapies presenting a significant clinical challenge. This study combines computational and experimental methods to identify and validate Antrocin, a natural sesquiterpene lactone, as a potential multi-target inhibitor of the BRAF/MEK/PI3K oncogenic pathway in CRC. Differential gene expression and mutational analyses were performed using public datasets (TCGA, TNMplot, GEPIA2, GSCA, PANDA, and cBioPortal) to assess the prevalence and clinical significance of BRAF, MEK, and PI3K alterations in CRC. In silico molecular docking, using AutoDock Vina, predicted strong binding affinities of Antrocin to BRAF (ΔG = −8.5 kcal/mol), MEK (ΔG = −7.3 kcal/mol), and PI3K (ΔG = −6.9 kcal/mol), comparable to those of FDA-approved inhibitors for BRAF (Dabrafenib), MEK (Trametinib), and PI3K (Alpelisib). Drug-likeness and ADME properties were evaluated via SwissADME and ADMETlab, supporting Antrocin’s potential as a drug candidate. In vitro assays using HCT116 and RKO CRC cell lines validated that Antrocin treatment suppressed cell viability, spheroid formation, and migration, accompanied by reduced expression levels of the oncogenic BRAF/MEK/PI3K signaling pathway. Antrocin-treated tumor-conditioned medium experiments demonstrated Antrocin’s ability to reduce the differentiation of cancer-associated fibroblasts and the polarization of M2 macrophages. Preclinical mouse xenograft experiments demonstrated a delay in tumor growth following treatment with Antrocin. These results suggest that Antrocin, identified through computational screening and validated experimentally, could be a promising multi-target agent to overcome therapy resistance in CRC.
- 9 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 8780
Open AccessIntegrated In Silico and Experimental Validation of Antrocin as a Plant-Derived Multi-Target Therapeutic for BRAF/MEK/PI3K-Driven Colorectal Cancer
Colorectal cancer (CRC) remains a leading cause of cancer-related death worldwide, with resistance to targeted therapies presenting a significant clinical challenge. This study combines computational and experimental methods to identify and validate Antrocin, a natural sesquiterpene lactone, as a potential multi-target inhibitor of the BRAF/MEK/PI3K oncogenic pathway in CRC. Differential gene expression and mutational analyses were performed using public datasets (TCGA, TNMplot, GEPIA2, GSCA, PANDA, and cBioPortal) to assess the prevalence and clinical significance of BRAF, MEK, and PI3K alterations in CRC. In silico molecular docking, using AutoDock Vina, predicted strong binding affinities of Antrocin to BRAF (ΔG = −8.5 kcal/mol), MEK (ΔG = −7.3 kcal/mol), and PI3K (ΔG = −6.9 kcal/mol), comparable to those of FDA-approved inhibitors for BRAF (Dabrafenib), MEK (Trametinib), and PI3K (Alpelisib). Drug-likeness and ADME properties were evaluated via SwissADME and ADMETlab, supporting Antrocin’s potential as a drug candidate. In vitro assays using HCT116 and RKO CRC cell lines validated that Antrocin treatment suppressed cell viability, spheroid formation, and migration, accompanied by reduced expression levels of the oncogenic BRAF/MEK/PI3K signaling pathway. Antrocin-treated tumor-conditioned medium experiments demonstrated Antrocin’s ability to reduce the differentiation of cancer-associated fibroblasts and the polarization of M2 macrophages. Preclinical mouse xenograft experiments demonstrated a delay in tumor growth following treatment with Antrocin. These results suggest that Antrocin, identified through computational screening and validated experimentally, could be a promising multi-target agent to overcome therapy resistance in CRC.
- Open Access
- 1 February 2024
- Published by University of Benin
- Vol. 8 (1) , 6005-6015
Determination of Antimalarial Properties of the Extract and Fractions of Brenania brieyi (Rubiaceae) Root In-Vivo Using Curative Model
Brenania brieyi (Rubiaceae) root is a medicinal plant, which has been widely used in ethno-medicine due to its antimalarial properties. The study aimed to evaluate the antimalarial potentials of B. brieyi root. Aqueous methanol extract of the roots of Brenania brieyi was prepared using cold maceration and dried in vacuo at 40 °C. The extract was fractionated using solvent-solvent partitioning with different solvents of varying polarity (n-hexane, ethyl acetate and methanol). Phytoconstituents of the extract and fractions were determined using standard procedures while the acute toxicity testing were carried out according to Lorkes method. Curative (8-day) test was employed for the antimalarial activity and the hematological parameters were also determined using standard procedures. Gas chromatography-mass spectroscopy (GC-MS) hyphenated technique was used to investigate volatile compounds present in the n-hexane fraction. Phytoconstituents present includes alkaloids, tannins, flavonoids, glycosides, carbohydrates, saponins while terpenoids is absent. Extracts at 200 and 400 mg/Kg dose levels caused a significant (p<0.05) comparable increase in parasitemia clearance of 86.36 % and 86.52 % respectively as opposed to 83.91 % clearance obtained from the standard (Arthemeter-lumefantrine). Ethyl acetate (87.89 %) and methanol (87.65 %) fractions gave higher clearance than Arthemeter-lumefantrine. The extract and fractions showed sufficient red blood cell restoration and reduction of white blood cell levels post treatment. GC-MS result shows the presence of twenty phyto-compounds, these scientific findings support the traditional use of Brenania brieyi root in management of malaria, for which the plant is known and used for.
- 1 February 2024
- Published by University of Benin
- Vol. 8 (1) , 6005-6015
Open AccessDetermination of Antimalarial Properties of the Extract and Fractions of Brenania brieyi (Rubiaceae) Root In-Vivo Using Curative Model
Brenania brieyi (Rubiaceae) root is a medicinal plant, which has been widely used in ethno-medicine due to its antimalarial properties. The study aimed to evaluate the antimalarial potentials of B. brieyi root. Aqueous methanol extract of the roots of Brenania brieyi was prepared using cold maceration and dried in vacuo at 40 °C. The extract was fractionated using solvent-solvent partitioning with different solvents of varying polarity (n-hexane, ethyl acetate and methanol). Phytoconstituents of the extract and fractions were determined using standard procedures while the acute toxicity testing were carried out according to Lorkes method. Curative (8-day) test was employed for the antimalarial activity and the hematological parameters were also determined using standard procedures. Gas chromatography-mass spectroscopy (GC-MS) hyphenated technique was used to investigate volatile compounds present in the n-hexane fraction. Phytoconstituents present includes alkaloids, tannins, flavonoids, glycosides, carbohydrates, saponins while terpenoids is absent. Extracts at 200 and 400 mg/Kg dose levels caused a significant (p<0.05) comparable increase in parasitemia clearance of 86.36 % and 86.52 % respectively as opposed to 83.91 % clearance obtained from the standard (Arthemeter-lumefantrine). Ethyl acetate (87.89 %) and methanol (87.65 %) fractions gave higher clearance than Arthemeter-lumefantrine. The extract and fractions showed sufficient red blood cell restoration and reduction of white blood cell levels post treatment. GC-MS result shows the presence of twenty phyto-compounds, these scientific findings support the traditional use of Brenania brieyi root in management of malaria, for which the plant is known and used for.
- 12 September 2023
- Published by University of Nigeria in AFRICAN JOURNAL OF PHARMACEUTICAL RESEARCH AND DEVELOPMENT
- Vol. 15 (3) , 43-52
ANTIMICROBIAL AND ANTITRYPANOSOMAL ACTIVITIES OF METHANOL ROOT EXTRACT AND FRACTIONS OF BRENANIA BRIEYI (DE WILD) PETIT (RUBIACEAE)
Brenania brieyi (Rubiaceae) is used in ethnomedicine for the treatment of malaria, microbial infections, trypanosomal disease, infertility and inflammatory disorders. The study determined antitrypanosomal and antimicrobial activities of extract and fractions of B. brieyi. Cold maceration and solvent-solvent partitioning were used to obtain the extract and respective fractions in order of their increasing polarity: n-hexane, dichloromethane, ethylacetate and absolute methanol. Phytochemical analysis, acute toxicity test and haematological parameters (Packed Cell Volume, parasitemia count) were carried out using standard procedures. Rapid matching and Agar dilution methods were used for antitrypanosomal and antimicrobial studies respectively. The extract (100, 200 and 400 mg/kg), fractions (200 mg/kg) and diminazine aceturate (3.5 mg/kg) were administered per oral. The extract was found to be safe up to 5000 mg/kg. The phytoconstituents present in the plant include tannins, terpenoids, flavonoids, phlobatannins, alkaloids, saponins, cardiac glycosides, quinones, steroids and phenols. The methanol extract of Brenania brieyi (MEBB) root showed significant (p < 0.05) dose-dependent inhibition of parasitemia. Antitrypanosomal activity of the fractions showed that the fractions possess varying degree of parasitemia clearance at 200 mg/kg dose. Methanol fraction produced the highest parasitemia clearance (6.98 ± 0.08 %), followed by n-hexane (7.13± 0.23 %), dichloromethane (7.43± 0.14 %) while ethylacetate fraction (9.00± 0.00 %) caused the least parasitemia clearance when compared with the positive control (0.00± 0.00 %). Haematological parameters and survival time were significantly (p < 0.05) increased, n-hexane fraction exhibited significant (p < 0.05) increase in survival time at 200 mg/kg (after 26 days). Methanol fraction at MICs of 7 to10 mg/ml showed inhibitory activity against Bacillus subtilis, Salmonella typhi, Escherichia coli, Klebsiella pneumonia, Staphylococcus aureus, Streptococcus mutant, Candida albicans and Aspergillus niger. The results obtained revealed that the extract and fractions possess antitrypanosomal and antimicrobial activity. The study provides scientific evidences for the traditional uses of the plant in treating infectious diseases.
- 12 September 2023
- Published by University of Nigeria in AFRICAN JOURNAL OF PHARMACEUTICAL RESEARCH AND DEVELOPMENT
- Vol. 15 (3) , 43-52
ANTIMICROBIAL AND ANTITRYPANOSOMAL ACTIVITIES OF METHANOL ROOT EXTRACT AND FRACTIONS OF BRENANIA BRIEYI (DE WILD) PETIT (RUBIACEAE)
Brenania brieyi (Rubiaceae) is used in ethnomedicine for the treatment of malaria, microbial infections, trypanosomal disease, infertility and inflammatory disorders. The study determined antitrypanosomal and antimicrobial activities of extract and fractions of B. brieyi. Cold maceration and solvent-solvent partitioning were used to obtain the extract and respective fractions in order of their increasing polarity: n-hexane, dichloromethane, ethylacetate and absolute methanol. Phytochemical analysis, acute toxicity test and haematological parameters (Packed Cell Volume, parasitemia count) were carried out using standard procedures. Rapid matching and Agar dilution methods were used for antitrypanosomal and antimicrobial studies respectively. The extract (100, 200 and 400 mg/kg), fractions (200 mg/kg) and diminazine aceturate (3.5 mg/kg) were administered per oral. The extract was found to be safe up to 5000 mg/kg. The phytoconstituents present in the plant include tannins, terpenoids, flavonoids, phlobatannins, alkaloids, saponins, cardiac glycosides, quinones, steroids and phenols. The methanol extract of Brenania brieyi (MEBB) root showed significant (p < 0.05) dose-dependent inhibition of parasitemia. Antitrypanosomal activity of the fractions showed that the fractions possess varying degree of parasitemia clearance at 200 mg/kg dose. Methanol fraction produced the highest parasitemia clearance (6.98 ± 0.08 %), followed by n-hexane (7.13± 0.23 %), dichloromethane (7.43± 0.14 %) while ethylacetate fraction (9.00± 0.00 %) caused the least parasitemia clearance when compared with the positive control (0.00± 0.00 %). Haematological parameters and survival time were significantly (p < 0.05) increased, n-hexane fraction exhibited significant (p < 0.05) increase in survival time at 200 mg/kg (after 26 days). Methanol fraction at MICs of 7 to10 mg/ml showed inhibitory activity against Bacillus subtilis, Salmonella typhi, Escherichia coli, Klebsiella pneumonia, Staphylococcus aureus, Streptococcus mutant, Candida albicans and Aspergillus niger. The results obtained revealed that the extract and fractions possess antitrypanosomal and antimicrobial activity. The study provides scientific evidences for the traditional uses of the plant in treating infectious diseases.
- Open Access
- 30 June 2022
- Published by University of Benin in Tropical Journal of Natural Product Research
- Vol. 5 (9) , 1551
In Vivo Investigation of the Aqueous Methanol Extracts of Leaves of Millettia aboensis (Hook. F.) Baker (Fabaceae) for Anti-Inflammatory Potentials
Inflammation is a serious disorder that is often accompanied by pain and discomfort. Millettia aboensis leaves are widely used traditionally in folkloric medicine in many parts of Africa for the management of different human ailments like inflammatory disorders, constipation, liver diseases. The phytochemical constituents and anti-inflammatory properties of aqueous methanol extract of Millettia aboensis leaf were investigated. The powdered leaf was exhaustively extracted with 95% aqueous methanol by cold maceration. The crude extract was concentrated n vacuo, weighed and percentage yield determined. Acute toxicity test was performed in accordance with the Lorke’s method. The phytochemical composition was screened using standard procedures, while the anti-inflammatory property was screened using the carrageenan-induced paw oedema model in rats. The acute toxicity test revealed that the plant has a high margin of safety. The phytochemical studies of the crude extract showed the presence of alkaloids, steroids, terpenoids, glycosides, tannins, flavonoids and saponins. The in vivo anti-inflammatory study revealed that at 200 mg/kg dose there was significant (p<0.05) inhibition of 79.06% on the inflammation of carrageenan-induced paw oedema after 4 hours as compared to the standard drug (piroxicam) that had 62.79% inhibition. These findings suggest that Millettia aboensis possesses anti-inflammatory potentials.
- 30 June 2022
- Published by University of Benin in Tropical Journal of Natural Product Research
- Vol. 5 (9) , 1551
Open AccessIn Vivo Investigation of the Aqueous Methanol Extracts of Leaves of Millettia aboensis (Hook. F.) Baker (Fabaceae) for Anti-Inflammatory Potentials
Inflammation is a serious disorder that is often accompanied by pain and discomfort. Millettia aboensis leaves are widely used traditionally in folkloric medicine in many parts of Africa for the management of different human ailments like inflammatory disorders, constipation, liver diseases. The phytochemical constituents and anti-inflammatory properties of aqueous methanol extract of Millettia aboensis leaf were investigated. The powdered leaf was exhaustively extracted with 95% aqueous methanol by cold maceration. The crude extract was concentrated n vacuo, weighed and percentage yield determined. Acute toxicity test was performed in accordance with the Lorke’s method. The phytochemical composition was screened using standard procedures, while the anti-inflammatory property was screened using the carrageenan-induced paw oedema model in rats. The acute toxicity test revealed that the plant has a high margin of safety. The phytochemical studies of the crude extract showed the presence of alkaloids, steroids, terpenoids, glycosides, tannins, flavonoids and saponins. The in vivo anti-inflammatory study revealed that at 200 mg/kg dose there was significant (p<0.05) inhibition of 79.06% on the inflammation of carrageenan-induced paw oedema after 4 hours as compared to the standard drug (piroxicam) that had 62.79% inhibition. These findings suggest that Millettia aboensis possesses anti-inflammatory potentials.